Michael P Sherman1, David H Adamkin2, Victoria Niklas3, Paula Radmacher2, Jan Sherman4, Fiona Wertheimer3, Karel Petrak5. 1. Division of Neonatology, Department of Child Health, University of Missouri, Columbia, MO. Electronic address: shermanmp@missouri.edu. 2. Division of Neonatal Medicine, Department of Pediatrics, University of Louisville, Louisville, KY. 3. Division of Neonatal Medicine, Children's Hospital Los Angeles, Keck School of Medicine at the University of Southern California, Los Angeles, CA. 4. Division of Neonatology, Department of Child Health, University of Missouri, Columbia, MO; Sinclair School of Nursing, University of Missouri, Columbia, MO. 5. Agennix Inc, Houston, TX.
Abstract
OBJECTIVE: To evaluate the safety and explore the efficacy of recombinant human lactoferrin (talactoferrin [TLf]) to reduce infection. STUDY DESIGN: We conducted a randomized, double blind, placebo-controlled trial in infants with birth weight of 750-1500 g. Infants receivedenteral TLf (n = 60) orplacebo (n = 60) on days 1 through 28 of life; the TLf dose was 150 mg/kg every 12 hours. Primary outcomes were bacteremia, pneumonia, urinary tract infection, meningitis, and necrotizing enterocolitis (NEC). Secondary outcomes were sepsis syndrome and suspected NEC. We recorded clinical, laboratory, and radiologic findings, along with diseases and adverse events, in a database used for statistical analyses. RESULTS:Demographic data were similar in the 2 groups of infants. We attributed no enteral or organ-specific adverse events to TLf. There were 2 deaths in the TLf group (1 each due to posterior fossa hemorrhage and postdischarge sudden infant death), and 1 death in the placebo group, due to NEC. The rate of hospital-acquired infections was 50% lower in the TLf group compared with the placebo group (P < .04), including fewer blood or line infections, urinary tract infections, and pneumonia. Fourteen infants in the TLf group weighing <1 kg at birth had no gram-negative infections, compared with only 3 of 14 such infants in the placebo group. Noninfectious outcomes were not statistically significantly different between the 2 groups, and there were no between-group differences in growth or neurodevelopment over a 1-year posthospitalization period. CONCLUSION: We found no clinical or laboratory toxicity and a trend toward less infectious morbidity in the infants treated with TLf. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00854633.
RCT Entities:
OBJECTIVE: To evaluate the safety and explore the efficacy of recombinant humanlactoferrin (talactoferrin [TLf]) to reduce infection. STUDY DESIGN: We conducted a randomized, double blind, placebo-controlled trial in infants with birth weight of 750-1500 g. Infants received enteral TLf (n = 60) or placebo (n = 60) on days 1 through 28 of life; the TLf dose was 150 mg/kg every 12 hours. Primary outcomes were bacteremia, pneumonia, urinary tract infection, meningitis, and necrotizing enterocolitis (NEC). Secondary outcomes were sepsis syndrome and suspected NEC. We recorded clinical, laboratory, and radiologic findings, along with diseases and adverse events, in a database used for statistical analyses. RESULTS: Demographic data were similar in the 2 groups of infants. We attributed no enteral or organ-specific adverse events to TLf. There were 2 deaths in the TLf group (1 each due to posterior fossa hemorrhage and postdischarge sudden infant death), and 1 death in the placebo group, due to NEC. The rate of hospital-acquired infections was 50% lower in the TLf group compared with the placebo group (P < .04), including fewer blood or line infections, urinary tract infections, and pneumonia. Fourteen infants in the TLf group weighing <1 kg at birth had no gram-negative infections, compared with only 3 of 14 such infants in the placebo group. Noninfectious outcomes were not statistically significantly different between the 2 groups, and there were no between-group differences in growth or neurodevelopment over a 1-year posthospitalization period. CONCLUSION: We found no clinical or laboratory toxicity and a trend toward less infectious morbidity in the infants treated with TLf. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00854633.
Authors: Linda McKibben; Teresa C Horan; Jerome I Tokars; Gabrielle Fowler; Denise M Cardo; Michele L Pearson; Patrick J Brennan Journal: Infect Control Hosp Epidemiol Date: 2005-06 Impact factor: 3.254
Authors: María Carmen Collado; María Cernada; Josef Neu; Gaspar Pérez-Martínez; María Gormaz; Máximo Vento Journal: Pediatr Res Date: 2015-03-11 Impact factor: 3.756
Authors: Michael P Sherman; John Minnerly; William Curtiss; Shaukat Rangwala; Scott T Kelley Journal: Neonatology Date: 2013-11-02 Impact factor: 4.035
Authors: Leslie C Pineda; Christoph P Hornik; Patrick C Seed; C Michael Cotten; Matthew M Laughon; Margarita Bidegain; Reese H Clark; P Brian Smith Journal: Early Hum Dev Date: 2015-07-27 Impact factor: 2.079
Authors: Theresa J Ochoa; Jaime Zegarra; Sicilia Bellomo; Cesar P Carcamo; Luis Cam; Anne Castañeda; Aasith Villavicencio; Jorge Gonzales; Maria S Rueda; Christie G Turin; Alonso Zea-Vera; Daniel Guillen; Miguel Campos; Linda Ewing-Cobbs Journal: J Pediatr Date: 2020-02-06 Impact factor: 4.406
Authors: C G Turin; A Zea-Vera; M S Rueda; E Mercado; C P Carcamo; J Zegarra; S Bellomo; L Cam; A Castaneda; T J Ochoa Journal: J Perinatol Date: 2017-01-26 Impact factor: 2.521
Authors: Nicholas D Embleton; Janet E Berrington; Jon Dorling; Andrew K Ewer; Edmund Juszczak; John A Kirby; Christopher A Lamb; Clare V Lanyon; William McGuire; Christopher S Probert; Stephen P Rushton; Mark D Shirley; Christopher J Stewart; Stephen P Cummings Journal: Front Nutr Date: 2017-05-08